CASC3 and Miyoshi myopathy: Nevertheless, the present findings argue that a mechanism-based strategy involving concomitant cIAP1 and proteasome antagonism warrants attention in MM, particularly in the setting of Btz refractoriness or other forms of drug resistance (e.g., microenvironmental).